The Federal Trade Commission on Tuesday released an interim report saying that powerful drug middlemen marked up drugs for cancer, AIDS, multiple sclerosis and other serious maladies far over the ...
Following a rough fourth quarter, we see the healthcare sector overall as undervalued, with a median discount to our fair ...
We recently published a list of 10 Hottest Large-Cap Stocks So Far in 2025. In this article, we are going to take a look at ...
SAN JOSE — An empty large store property within a San Jose retail center has been bought by a Bay Area investment group for ...
Big-box drugstores like CVS and Walgreens are closing thousands of stores across the country, including some in the St. Louis ...
From 2017 to 2022, the companies marked up prices at their pharmacies by hundreds or thousands of percent, netting them $7.3 ...
The U.S. Federal Trade Commission (FTC) has slammed pharmacy benefit managers (PBMs) owned by UnitedHealth ($UNH), CVS Health ...
FTC report reveals significant markups by top PBMs on specialty drugs, driving $7.3 billion in revenue and raising costs for ...
Snyders Pharmacy, located in Oregon’s Ace Hardware, announced it has suspended operation of its drive-thru due to lack of ...
Zacks.com on MSN6h
FTC Report Reveals PBM Practices Impacting Competition and Drug CostsThe Federal Trade Commission (“FTC”) released its second interim report on Jan. 14, 2025, accusing pharmacy benefit managers (PBMs) of marking up the prices of specialty generic drugs. FTC’s report ...
UnitedHealth (UNH) stock and CVS Health (CVS) stock were named top picks at Piper Sandler on a potential hike in Medicare ...
The FDC released a second highly critical report of PBMs, which may provide further impetus for legislative action to curb ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback